Telix Pharmaceuticals Limited announced the launch of an informational microsite for the company’s illumet cold kit – illumet.com. Illumet is an investigational product for the preparation of 68Ga-HBED-CC-PSMA-11 (68Ga-PSMA). The website is designed to provide a focused information repository for clinical researchers interested in learning more about illumet™ and the preparation of 69Ga-PSMA. Illumet is available for investigational use only as part of an FDA Investigational New Drug (IND) application. 68Ga-PSMA has been shown to illuminate prostate cancer cells expressing Prostate-Specific Membrane Antigen (PSMA) with Positron Emission Tomography (PET). Oncologists, radiologists and nuclear medicine physicians around the globe have studied PSMA expression in thousands of prostate cancer patients using with PET imaging. The illumet solution makes the preparation of 68Ga-PSMA a highly accessible, cost-effective and streamlined process. With the illumet kit, nuclear pharmacies can now prepare a sterile cGMP dose of 68Ga-PSMA at room temperature with no additional production hardware. Until now, synthesizer-based approaches have been used to produce 68Ga-PSMA, requiring specialized and costly infrastructure. The illumet solution delivers a rapid and reproducible preparation process via a single-use disposable kit, without the use of expensive or resource-intensive radiochemistry production systems.